Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026)
Upstream Bio's quarterly Income from Continuing Operations came in at 40561000.0 in Q1 2026, down 48.74% year-on-year from 79125722.15 in Q1 2025, and up 4.59% quarter-over-quarter from 42513000.0 in Q4 2025.
Upstream Bio has reported Income from Continuing Operations for 4 years, with the latest figure at 40561000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 48.74% year-over-year to 40561000.0; the trailing twelve-month figure through Mar 2026 stood at 156719000.0 (down 97.97% YoY), and the FY2025 full-year result was 143428000.0, down 118.5% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 40561000.0, up from 42513000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 7859000.0 in Q3 2023, with the low at 42513000.0 in Q4 2025.
- Average Income from Continuing Operations over 4 years is 24572727.27, with a median of 21242000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations sank 172.22% in 2025 and sank 48.74% in 2026.
- Tracing UPB's Income from Continuing Operations over 4 years: stood at 12811000.0 in 2023, then slumped by 65.81% to 21242000.0 in 2024, then slumped by 100.14% to 42513000.0 in 2025, then increased by 4.59% to 40561000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 40561000.0 (Q1 2026), 42513000.0 (Q4 2025), and 33729000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | -40.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.56 Mn |
| Dec 31, 2025 | -42.51 Mn |
| Sep 30, 2025 | -33.73 Mn |
| Jun 30, 2025 | -39.92 Mn |
| Mar 31, 2025 | -27.27 Mn |
| Dec 31, 2024 | -21.24 Mn |
| Sep 30, 2024 | -15.99 Mn |
| Jun 30, 2024 | -14.66 Mn |
| Mar 31, 2024 | -13.75 Mn |
| Dec 31, 2023 | -12.81 Mn |
| Sep 30, 2023 | -7.86 Mn |